» Articles » PMID: 35893800

Design and Validation of Nanofibers Made of Self-Assembled Peptides to Become Multifunctional Stimuli-Sensitive Nanovectors of Anticancer Drug Doxorubicin

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Jul 27
PMID 35893800
Authors
Affiliations
Soon will be listed here.
Abstract

Self-assembled peptides possess remarkable potential as targeted drug delivery systems and key applications dwell anti-cancer therapy. Peptides can self-assemble into nanostructures of diverse sizes and shapes in response to changing environmental conditions (pH, temperature, ionic strength). Herein, we investigated the development of self-assembled peptide-based nanofibers (NFs) with the inclusion of a cell-penetrating peptide (namely gH625) and a matrix metalloproteinase-9 (MMP-9) responsive sequence, which proved to enhance respectively the penetration and tumor-triggered cleavage to release Doxorubicin in Triple Negative Breast Cancer cells where MMP-9 levels are elevated. The NFs formulation has been optimized via critical micelle concentration measurements, fluorescence, and circular dichroism. The final nanovectors were characterized for morphology (TEM), size (hydrodynamic diameter), and surface charge (zeta potential). The Doxo loading and release kinetics were studied in situ, by optical microspectroscopy (fluorescence and surface-enhanced Raman scattering-SERS). Confocal spectral imaging of the Doxo fluorescence was used to study the TNBC models in vitro, in cells with various MMP-9 levels, the drug delivery to cells as well as the resulting cytotoxicity profiles. The results confirm that these NFs are a promising platform to develop novel nanovectors of Doxo, namely in the framework of TNBC treatment.

Citing Articles

Self-assembled lipid-based nanoparticles for chemotherapy against breast cancer.

Liu S Front Bioeng Biotechnol. 2024; 12:1482637.

PMID: 39534673 PMC: 11555772. DOI: 10.3389/fbioe.2024.1482637.


Targeted Delivery to Dying Cells Through P-Selectin-PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in Liver Injury Models.

Lien T, Sun D, Chang H Cells. 2024; 13(21.

PMID: 39513885 PMC: 11545035. DOI: 10.3390/cells13211778.


Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.

Bellavita R, Piccolo M, Leone L, Ferraro M, Dardano P, De Stefano L Int J Nanomedicine. 2024; 19:6057-6084.

PMID: 38911501 PMC: 11193445. DOI: 10.2147/IJN.S453958.


Strategic Single-Residue Substitution in the Antimicrobial Peptide Esc(1-21) Confers Activity against , Including Drug-Resistant and Biofilm Phenotype.

Loffredo M, Casciaro B, Bellavita R, Troiano C, Brancaccio D, Cappiello F ACS Infect Dis. 2024; 10(7):2403-2418.

PMID: 38848266 PMC: 11250030. DOI: 10.1021/acsinfecdis.4c00130.


A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo.

Li J, Zhou Y, Su Z, Li X, Zhang L, Li S Molecules. 2024; 29(6).

PMID: 38542884 PMC: 10974526. DOI: 10.3390/molecules29061247.


References
1.
Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

2.
Hwang S, Park S, Kwon Y . Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol Ther. 2019; 199:30-57. DOI: 10.1016/j.pharmthera.2019.02.006. View

3.
Falanga A, Galdiero M, Galdiero S . Membranotropic Cell Penetrating Peptides: The Outstanding Journey. Int J Mol Sci. 2015; 16(10):25323-37. PMC: 4632803. DOI: 10.3390/ijms161025323. View

4.
Valiante S, Falanga A, Cigliano L, Iachetta G, Busiello R, Marca V . Peptide gH625 enters into neuron and astrocyte cell lines and crosses the blood-brain barrier in rats. Int J Nanomedicine. 2015; 10:1885-98. PMC: 4364164. DOI: 10.2147/IJN.S77734. View

5.
Lehmann B, Jovanovic B, Chen X, Estrada M, Johnson K, Shyr Y . Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6):e0157368. PMC: 4911051. DOI: 10.1371/journal.pone.0157368. View